stockrowXencor, Inc.
XNCR Healthcare Biotechnology
Xencor, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $125.6 million, up 13.7% from fiscal 2024.
- Revenue
- +17.5%
- EPS
- +29.3%
- Free cash flow
- −52.9%
Quarter to June 2026, against a year earlier
Follow XNCR
Alert me
Xencor, Inc. (XNCR) Return on assets
Xencor, Inc.'s return on assets over the twelve months to 30 June 2026 was −20.4%, down 10.3 percentage points from fiscal 2025 (−10.1%). Over the past ten years it has ranged from −24.3% (fiscal 2024) to 14.2% (fiscal 2016); the current reading is higher than 55% of that period. That is above the Biotechnology industry median of −45.6% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −10.1% | 14.21 |
| FY2024 | −24.3% | (9.57) |
| FY2023 | −14.7% | (8.15) |
| FY2022 | −6.55% | (17.27) |
| FY2021 | 10.7% | 20.82 |
| FY2020 | −10.1% | (14.41) |
| FY2019 | 4.31% | 18.87 |
| FY2018 | −14.6% | (5.16) |
| FY2017 | −9.40% | (23.60) |
| FY2016 | 14.2% | 27.01 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| ADMA ADMA Biologics Inc compare | 28.0% |
| BEAM Beam Therapeutics Inc. compare | −8.40% |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −18.2% |
| XNCR Xencor, Inc. | −20.4% |
| NAMS NewAmsterdam Pharma Company N.V. compare | −27.8% |
| MBX MBX Biosciences, Inc. compare | −31.3% |
| RXRX Recursion Pharmaceuticals, Inc. compare | −36.3% |
| RCUS Arcus Biosciences, Inc. compare | −50.6% |
| PHVS Pharvaris N.V. compare | −64.4% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on XNCR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement